Related Experiment Video

Updated: Aug 3, 2025

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

9.6K

[GLP-1 Receptor Agonists: For Which Patients with Type-2 Diabetes?]

Tobias Mächler1, Peter Wiesli1

  • 1Kantonsspital Frauenfeld, Frauenfeld, Schweiz.

Praxis
|April 12, 2023
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly reduce cardiorenal risks in type-2 diabetes patients. Early prescription and combination therapy with SGLT-2 inhibitors are recommended for high-risk individuals.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Context:

  • Type-2 diabetes management.
  • Cardiovascular outcome trials (CVOTs) for antidiabetics.
  • Emerging evidence on cardiorenal benefits of specific drug classes.

Purpose:

  • To evaluate the role of GLP-1 receptor agonists in type-2 diabetes.
  • To determine optimal patient populations for GLP-1 receptor agonist therapy.
  • To inform clinical practice regarding early and combination therapy.

Summary:

  • GLP-1 receptor agonists, similar to SGLT-2 inhibitors, demonstrate significant reduction in cardiorenal events in type-2 diabetes.
  • These benefits are observed irrespective of concomitant medications.
  • Early initiation of GLP-1 receptor agonists is supported by current evidence.

Impact:

  • Supports earlier and broader use of GLP-1 receptor agonists in type-2 diabetes treatment.
  • Highlights combination therapy with SGLT-2 inhibitors as a viable strategy for high cardiovascular risk patients.
  • Aims to improve long-term outcomes and reduce cardiorenal complications in type-2 diabetes.
Keywords:
Agonistes des récepteurs GLP-1Diabetes mellitus Typ 2GLP-1 receptor agonistsGLP-1-Rezeptor-AgonistenHerzinsuffizienzMACENierenfunktionsstörungdiabète de type 2heart failureinsuffisance cardiaqueinsuffisance rénalerenal failuretype-2 diabetes

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

244
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
373
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
195
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
247
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
220
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
224
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
264